Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 98.68 USD 0.5% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Axsome Therapeutics Inc?
Write Note

Wall Street
Price Targets

AXSM Price Targets Summary
Axsome Therapeutics Inc

Wall Street analysts forecast AXSM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXSM is 130.69 USD with a low forecast of 71.71 USD and a high forecast of 189 USD.

Lowest
Price Target
71.71 USD
27% Downside
Average
Price Target
130.69 USD
32% Upside
Highest
Price Target
189 USD
92% Upside

AXSM Last Price Targets
Axsome Therapeutics Inc

The latest public price target was made on Nov 12, 2024 by Yatin Suneja from Guggenheim , who expects AXSM stock to rise by 37% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Yatin Suneja
Guggenheim
135 USD
Upside 37%
1 week ago
Nov 12, 2024
Axsome Therapeutics (AXSM) PT Raised to $135 at Guggenheim
StreetInsider
Graig Suvannavejh
Mizuho Securities
106 USD
Upside 7%
2 months ago
Sep 11, 2024
Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
StreetInsider
Cerena Chen
Wells Fargo
140 USD
Upside 42%
2 months ago
Sep 3, 2024
Axsome Therapeutics initiated with an Overweight at Wells Fargo
TheFly
Raghuram Selvaraju
H.C. Wainwright
180 USD
Upside 82%
3 months ago
Aug 6, 2024
Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright
TheFly
Jason Gerberry
Bank of America Securities
106 USD
Upside 7%
3 months ago
Aug 6, 2024
BofA Securities Upgrades Axsome Therapeutics (AXSM) to Buy
StreetInsider
Leonid Timashev
RBC Capital
131 USD
Upside 33%
4 months ago
Jul 22, 2024
RBC Capital Reiterates Outperform Rating on Axsome Therapeutics (AXSM)
StreetInsider
Leonid Timashev
RBC Capital
130 USD
Upside 32%
5 months ago
Jun 5, 2024
Axsome Therapeutics (AXSM) PT Raised to $130 at RBC Capital
StreetInsider
David Amsellem
Piper Sandler
115 USD
Upside 17%
5 months ago
May 28, 2024
Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
StreetInsider
Vikram Purohit
Morgan Stanley
115 USD
Upside 17%
6 months ago
Apr 29, 2024
Morgan Stanley Upgrades Axsome Therapeutics (AXSM) to Overweight, 'attractive risk/reward heading into 2H24'
StreetInsider
Graig Suvannavejh
Mizuho Securities
109 USD
Upside 10%
7 months ago
Mar 28, 2024
Axsome Therapeutics (AXSM) PT Raised to $109 at Mizuho
StreetInsider
Joel Beatty
Robert W. Baird
108 USD
Upside 9%
8 months ago
Mar 18, 2024
Baird Starts Axsome Therapeutics (AXSM) at Outperform, 'we anticipate the sales trajectory will remain strong'
StreetInsider
Show More Price Targets
Show Less Price Targets
Yatin Suneja
Guggenheim
Price Target 135 USD
Upside/Downside 37%
View Source
Graig Suvannavejh
Mizuho Securities
Price Target 106 USD
Upside/Downside 7%
View Source
Cerena Chen
Wells Fargo
Price Target 140 USD
Upside/Downside 42%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 180 USD
Upside/Downside 82%
View Source
Jason Gerberry
Bank of America Securities
Price Target 106 USD
Upside/Downside 7%
View Source
Leonid Timashev
RBC Capital
Price Target 131 USD
Upside/Downside 33%
View Source
Leonid Timashev
RBC Capital
Price Target 130 USD
Upside/Downside 32%
View Source
David Amsellem
Piper Sandler
Price Target 115 USD
Upside/Downside 17%
View Source
Vikram Purohit
Morgan Stanley
Price Target 115 USD
Upside/Downside 17%
View Source
Graig Suvannavejh
Mizuho Securities
Price Target 109 USD
Upside/Downside 10%
View Source
Joel Beatty
Robert W. Baird
Price Target 108 USD
Upside/Downside 9%
View Source
Show More Price Targets
Show Less Price Targets
Axsome Therapeutics Inc Competitors:
Price Targets
SDZ
Sandoz Group AG
4% Upside
EAPI
Euroapi SAS
3% Downside
AQST
Aquestive Therapeutics Inc
125% Upside
FUM
Futura Medical PLC
319% Upside
ITCI
Intra-Cellular Therapies Inc
19% Upside
MARKSANS
Marksans Pharma Ltd
6% Downside

Revenue
Forecast

Revenue Estimate
Axsome Therapeutics Inc

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 3 years is 61%.

N/A
Past Growth
61%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Axsome Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AXSM's stock price target?
Price Target
130.69 USD

According to Wall Street analysts, the average 1-year price target for AXSM is 130.69 USD with a low forecast of 71.71 USD and a high forecast of 189 USD.

What is Axsome Therapeutics Inc's Revenue forecast?
Projected CAGR
61%

The compound annual growth rate of Axsome Therapeutics Inc's revenue for the next 3 years is 61%.

Back to Top